When emergency room physicians face a critically high potassium level, every minute counts. New clinical trial data presented at the American Society of Nephrology Kidney Week 2026 in Denver, Colorado, offers a clearer path forward in managing this dangerous medical emergency.
The randomized clinical trial evaluated adults aged 18 and older presenting with severe hyperkalemia. Originally designed with an inclusion threshold of 6.0 mmol/L, the trial protocol was amended to widen eligibility to patients with serum potassium levels at or above 5.5 mmol/L. Investigators then assigned 398 analyzed participants across three distinct treatment arms to see which approach lowered potassium levels the fastest.
Evaluating Single Versus Combination Treatments in the Emergency Room
Researchers divided the patient cohort into three groups to compare therapeutic efficacy. One group received nebulized salbutamol dosed at 10 mg administered over 30 minutes. A second group received intravenous insulin at 10 units paired with 500 mL of 10% dextrose delivered over the same 30-minute window. The third group received both therapies concurrently at those exact doses.
The primary outcome measured the mean change in serum potassium from baseline to the 60-minute mark, capturing the immediate biological impact of each intervention. At baseline, the median age of the analyzed patients stood at 76 years, with 33% identifying as women, and a median baseline serum potassium level of 6.2 mmol/L. The results showed a clear hierarchy in potassium reduction:
- Salbutamol alone achieved a mean decrease of 0.8 mmol/L.
- Insulin and dextrose alone achieved a mean decrease of 1.1 mmol/L.
- Combination therapy achieved a mean decrease of 1.3 mmol/L.
The combination approach outperformed salbutamol alone by an adjusted difference of 0.44 mmol/L and outpaced insulin and dextrose alone by an adjusted difference of 0.22 mmol/L. Meanwhile, adverse events remained comparable across all groups, with the exception of hyperglycemia, which occurred less frequently among patients treated solely with salbutamol.
Future Research Must Determine If Rapid Potassium Reduction Lowers Mortality
Despite the clear biochemical advantage seen at 60 minutes, whether faster potassium lowering directly translates to improved patient-oriented outcomes remains unproven. Investigators noted that the trial was not powered to measure patient-oriented outcomes. Future research will need to enroll larger patient cohorts to determine if rapid reductions in serum potassium reliably decrease overall mortality and adverse clinical events in emergency settings.
